Page last updated: 2024-08-21

indazoles and olaparib

indazoles has been researched along with olaparib in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	26 (56.52)	24.3611
2020's	20 (43.48)	2.80

Authors

Authors	Studies
André, F; Ashworth, A; Bajrami, I; Dorvault, N; Elliott, R; Fontebasso, Y; Friboulet, L; Lord, CJ; Olaussen, KA; Postel-Vinay, S; Soria, JC	1
Konstantinopoulos, PA; Liu, JF; Matulonis, UA	1
Matsumoto, K; Onda, T; Yaegashi, N	1
DiGiammarino, EL; Donawho, CK; Gao, W; Hopkins, TA; Johnson, EF; Maag, D; Olson, AM; Osterling, DJ; Panchal, SC; Rodriguez, LE; Shi, Y; Solomon, LR; Stolarik, DF; Wilsbacher, JL	1
Seimiya, H	1
Agnihotri, S; Buczkowicz, P; Chornenkyy, Y; Dirks, PB; Garzia, L; Golbourn, B; Hawkins, C; Leung, S; Rakopoulos, P; Rutka, JT; Siddaway, R; Taylor, MD; Yu, M	1
Cohen, MS; Ekblad, T; Karlberg, T; Löw, M; Moche, M; Pinto, AF; Schüler, H; Thorsell, AG; Trésaugues, L	1
George, TJ; Hromas, R; Jaiswal, AS; Jones, D; Najmunnisa, N; Sidhu, GS; Srinivasan, G; Wilcoxen, K; Williamson, EA	1
Chougnet, C; Goldwirt, L; Huynh, HH; Le Maignan, C; Madelaine, I; Mourah, S; Plé, A; Pressiat, C; Sauvageon, H	1
Gillard, M; Lee, JM; Lipkowitz, S; Zimmer, AS	1
Mountzios, G; Papadimitriou, CA; Papadimitriou, M	1
Domchek, SM	1
Al-Kawaz, A; Ali, R; Band, V; Green, AR; Madhusudan, S; Mesquita, KA; Miligy, IM; Mirza, S; Rakha, EA; Seedhouse, C; Toss, MS	1
Baldini, C; Banerjee, S; Battisti, NML; Dumas, L; Kadambi, S; Lichtman, SM; Liposits, G; Loh, KP; Soto-Perez-de-Celis, E	1
Fisher, M; Guy, H; Walder, L	2
Nugent, E; Smith, JA; Tomasino, T; Tran, AT; Zhong, L	1
Wu, L; Zhong, L	1
Coleman, RL; Kurnit, KC; Westin, SN	1
Bai, H; Jiang, X; Li, W; Li, X; Zhang, Z	1
Cohn, DE; Ehrisman, JA; Foote, JR; Havrilesky, LJ; Jewell, E; Liang, MI; Secord, AA	1
Campbell, JD; Chapman, RH; Kumar, VM; McQueen, RB; Whittington, MD	1
Bedel, J; Cameron, T; Goble, S; Isaacson, J; Maloney, L; Wallace, K	1
Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; de Bono, JS; Kaye, SB; Lord, CJ; Mateo, J; Oaknin, A; Serra, V; Tutt, A	1
Aguilera, J; Behbakht, K; Bitler, BG; Brennecke, EP; Cittelly, DM; Ferguson, R; Joglar, AM; Kim, H; McMellen, A; Moldovan, GL; Nurmemmedov, E; Sikora, MJ; Thakar, T; Watson, ZL; Wilson, H; Yamamoto, TM	1
Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y	1
Amaravadi, RK; Bast, RC; Becker, SE; Heinzen, EP; Hou, X; Llombart-Cussac, A; Lu, Z; Matias-Guiu, X; Maurer, MJ; Oberg, AL; Pang, L; Poveda, A; Rask, P; Romero, I; Rubio, MJ; Santacana, M; Santiago-O'Farrill, JM; Weroha, SJ	1
Rodrigues, M	1
Al-Lazikani, B; Ameratunga, M; Antolin, AA; Banerji, U; Clarke, PA; Workman, P	1
Bai, J; Kristeleit, R; Monk, BJ; Moore, KN; Tewari, KS; Wolford, JE	1
Chase, DM; Eakin, CM; Ewongwo, A; Monk, BJ; Pendleton, L	1
Coleman, RL; Onstad, M; Westin, SN	1
Aragón, IM; Castro, E; Cattrini, C; Cendón, Y; López-Casas, PP; Lozano, R; Olmos, D	1
Penn, CA; Walsh, CS; Wong, MS	1
Grewal, K; Tabbara, IA	1
Luger, K; Roberts, G; Rudolph, J	1
Delaye, M; Rodrigues, M	1
Guo, Q; Liu, L; Lu, W; Ma, Z; Sun, X; Wang, S; You, J; Zhang, Y; Zhao, Z	1
Chan, AL; Lang, HC; Leung, JH; Lo, HF; Wang, SY	1
Cai, Z; Cao, D; Chang, C; Jiang, Z; Liu, C; Mu, M; Shen, C; Yin, X; Yin, Y; Zhang, B; Zhang, L; Zhao, Z	1
Artali, R; Aviñó, A; Dallavalle, S; Eritja, R; Gargallo, R; Mattio, LM; Mazzini, S; Musso, L; Pisano, C; Princiotto, S	1
Bellesoeur, A; Beuzeboc, P; Diéras, V; Neuzillet, C; Rodrigues, M; Saint-Ghislain, M; Salaün, H; Stern, MH	1
Azaïs, H; Bats, AS; Bentivegna, E; Blons, H; Delanoy, N; Durdux, C; Koual, M; Laurent-Puig, P; Le Frère-Belda, MA; Le Gac, M; Nguyen-Xuan, HT; Perkins, G	1
Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F	1
Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M	1

Reviews

18 review(s) available for indazoles and olaparib

Article	Year
PARP inhibitors in ovarian cancer: current status and future promise. Gynecologic oncology, 2014, Volume: 133, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2014
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids	2015
[Cancer therapy by PARP inhibitors]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Enzyme Inhibitors; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Mutation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair	2015
Update on PARP Inhibitors in Breast Cancer. Current treatment options in oncology, 2018, 04-11, Volume: 19, Issue:5 Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival	2018
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer treatment reviews, 2018, Volume: 67 Topics: Benzamides; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms	2018
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Journal of geriatric oncology, 2019, Volume: 10, Issue:2 Topics: Aged; Aged, 80 and over; Breast Neoplasms; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations	2019
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Current treatment options in oncology, 2018, 11-15, Volume: 19, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:4 Topics: Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2019
A decade of clinical development of PARP inhibitors in perspective. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 09-01, Volume: 30, Issue:9 Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genomic Instability; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors	2019
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current drug targets, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2020
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs, 2020, Volume: 80, Issue:15 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Maintenance Chemotherapy; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Randomized Controlled Trials as Topic; Recombinational DNA Repair; United States; United States Food and Drug Administration	2020
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. British journal of cancer, 2021, Volume: 124, Issue:3 Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Clinical Trials as Topic; DNA Damage; DNA Repair; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; High-Throughput Nucleotide Sequencing; Humans; Immune Checkpoint Inhibitors; Indazoles; Indoles; Male; Phthalazines; Piperazines; Piperidines; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Prognosis; Prostatic Neoplasms	2021
PARP Inhibitors in Prostate Cancer. Anticancer research, 2021, Volume: 41, Issue:2 Topics: Animals; BRCA1 Protein; BRCA2 Protein; Genetic Predisposition to Disease; Humans; Indazoles; Indoles; Male; Mutation; Neoplasm Metastasis; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Treatment Outcome	2021
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecologic oncology, 2021, Volume: 162, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Humans; Incidence; Indazoles; Neoplasms; Phthalazines; Piperazines; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Time Factors	2021
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. Pharmacological research, 2021, Volume: 172 Topics: Humans; Indazoles; Indoles; Neoplasms; Network Meta-Analysis; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic	2021
[Homologous recombination deficiency and PARP inhibitors in therapeutics]. Bulletin du cancer, 2022, Volume: 109, Issue:1 Topics: Breast Neoplasms; DNA Damage; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Indoles; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Recombinational DNA Repair	2022
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers]. Bulletin du cancer, 2022, Volume: 109, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; DNA Damage; DNA Repair-Deficiency Disorders; Endometrial Neoplasms; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Papillomavirus Infections; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Uterine Cervical Neoplasms	2022
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer. Bulletin du cancer, 2021, Volume: 108, Issue:9S1 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021

Other Studies

28 other study(ies) available for indazoles and olaparib

Article	Year
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene, 2013, Nov-21, Volume: 32, Issue:47 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; High-Throughput Screening Assays; Humans; Indazoles; Lung Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Isoforms; Rad51 Recombinase; RNA Interference; RNA, Small Interfering	2013
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Molecular cancer research : MCR, 2015, Volume: 13, Issue:11 Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Tolerance; Humans; Indazoles; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2015
Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular cancer therapeutics, 2015, Volume: 14, Issue:11 Topics: Animals; Astrocytoma; Benzimidazoles; Blotting, Western; Brain Stem Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Child; Combined Modality Therapy; Glioma; Humans; Indazoles; Kaplan-Meier Estimate; Linear Models; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pons; Radiotherapy; Xenograft Model Antitumor Assays	2015
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Benzimidazoles; Enzyme Inhibitors; HEK293 Cells; Humans; Indazoles; Models, Molecular; Phenanthrenes; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tankyrases	2017
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:4 Topics: Cell Line, Tumor; Clone Cells; DNA Repair; Humans; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Phthalazines; Piperazines; Piperidines; Pleural Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Tumor Suppressor Proteins; Ubiquitin Thiolesterase	2017
PARP inhibitors for ovarian cancer. The Medical letter on drugs and therapeutics, 2017, 12-04, Volume: 59, Issue:1535 Topics: Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome	2017
Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic drug monitoring, 2018, Volume: 40, Issue:3 Topics: Angiogenesis Inhibitors; Anilides; Chromatography, Liquid; Humans; Indazoles; Nitriles; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry	2018
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine	2018
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma Cancer research, 2018, 12-15, Volume: 78, Issue:24 Topics: Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Cycle; Cell Line, Tumor; Chemoprevention; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA Repair; Female; Germ-Line Mutation; HeLa Cells; Humans; Indazoles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Synthetic Lethal Mutations; X-ray Repair Cross Complementing Protein 1	2018
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. PharmacoEconomics, 2019, Volume: 37, Issue:3 Topics: Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States	2019
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:12 Topics: Clinical Decision-Making; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States	2018
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of medical economics, 2019, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States	2019
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic oncology, 2019, Volume: 152, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Indazoles; Indoles; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic	2019
Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". PharmacoEconomics, 2019, Volume: 37, Issue:7 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2019
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'. PharmacoEconomics, 2019, Volume: 37, Issue:7 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2019
Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". PharmacoEconomics, 2019, Volume: 37, Issue:8 Topics: Cost-Benefit Analysis; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2019
Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular carcinogenesis, 2019, Volume: 58, Issue:10 Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indazoles; Indoles; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Wnt Signaling Pathway	2019
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer, 2020, 02-15, Volume: 126, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Xenograft Model Antitumor Assays	2020
[PARP inhibitors in first-line of ovarian cancers]. Bulletin du cancer, 2020, Volume: 107, Issue:1 Topics: Benzimidazoles; Clinical Trials as Topic; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific reports, 2020, 02-17, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Dyrk Kinases; HEK293 Cells; Humans; Indazoles; Indoles; Isoenzymes; Molecular Docking Simulation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polypharmacology; Protein Binding; Protein Interaction Domains and Motifs; Protein Serine-Threonine Kinases; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Substrate Specificity	2020
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecologic oncology, 2020, Volume: 157, Issue:2 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indazoles; Indoles; Infusions, Intravenous; Markov Chains; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; United States	2020
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecologic oncology, 2020, Volume: 159, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community Health Centers; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Female; Follow-Up Studies; Gynecology; Humans; Indazoles; Indoles; Medical Oncology; Medication Therapy Management; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Workload	2020
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. JAMA network open, 2020, 12-01, Volume: 3, Issue:12 Topics: Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Ovarian Epithelial; Computing Methodologies; Cost-Benefit Analysis; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Maintenance Chemotherapy; Medicare; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States	2020
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs. Nature communications, 2021, 02-02, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzimidazoles; Binding Sites; Carrier Proteins; Catalysis; Catalytic Domain; DNA Repair Enzymes; Humans; Indazoles; Indoles; Nuclear Proteins; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Protein Binding	2021
[New drug approval: Olaparib and niraparib - first line in ovarian cancer]. Bulletin du cancer, 2021, Volume: 108, Issue:4 Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Female; Humans; Indazoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:3 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines	2022
Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region. International journal of molecular sciences, 2021, Aug-14, Volume: 22, Issue:16 Topics: Benzimidazoles; DNA; G-Quadruplexes; Humans; Indazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic	2021
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy. International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:8 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors	2022